erlotinib hydrochloride has been researched along with Neoplasms, Bronchial in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (66.67) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Drpa, G; Kukulj, S; Manojlovic, S; Sreter, KB | 1 |
| Hsu, JH; Li, MF; Shiau, EL; Wu, MT | 1 |
| Dittmann, K; Fehrenbacher, B; Huber, S; Mayer, C; Paasch, A; Rodemann, HP; Schaller, M | 1 |
| Gaya, A; Khorshid, M; Plowman, PN; Walther, JC | 1 |
| Zalcman, G | 1 |
| Pérol, M | 1 |
| Bréchot, JM | 1 |
| Quoix, E | 1 |
| Soria, JC | 1 |
9 other study(ies) available for erlotinib hydrochloride and Neoplasms, Bronchial
| Article | Year |
|---|---|
Erlotinib for coexisting typical bronchial carcinoid and advanced lung adenocarcinoma: does the epidermal growth factor receptor mutation status matter?
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Bronchial Neoplasms; Carcinoid Tumor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasms, Multiple Primary; Protein Kinase Inhibitors | 2018 |
Recurrent respiratory papillomatosis with lung involvement and malignant transformation.
Topics: Bronchial Neoplasms; Bronchoscopy; Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; Chemoradiotherapy, Adjuvant; Contrast Media; Disease Progression; Erlotinib Hydrochloride; Humans; Male; Middle Aged; Papillomavirus Infections; Protein Kinase Inhibitors; Quinazolines; Respiratory Tract Infections; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Nuclear EGFR renders cells radio-resistant by binding mRNA species and triggering a metabolic switch to increase lactate production.
Topics: Blotting, Western; Bronchial Neoplasms; Cell Line, Tumor; Cell Nucleus; Dasatinib; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression; Head and Neck Neoplasms; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lactic Acid; Nuclear Proteins; Oxadiazoles; Protein Kinase Inhibitors; Pyrazoles; Radiation Tolerance; RNA, Messenger | 2015 |
Cross-over response to erlotinib of brain metastatic disease from bronchial adenocarcinoma after gefitinib failure, and an unusual rash.
Topics: Adenocarcinoma; Antineoplastic Agents; Brain Neoplasms; Bronchial Neoplasms; Drug Hypersensitivity; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Middle Aged; Quinazolines; Skin Diseases, Vesiculobullous | 2006 |
[EGFR pathway and mechanism of action of tyrosine kinase inhibitors].
Topics: Bronchial Neoplasms; Carcinoma, Non-Small-Cell Lung; Chromosomes, Human, Pair 7; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Genes, erbB-2; Genes, ras; Humans; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Respiratory Mucosa | 2007 |
[Clinical results observed with tyrosine kinase inhibitors].
Topics: Bronchial Neoplasms; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2007 |
[Associations of tyrosine kinase inhibitors with chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bronchial Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Erlotinib Hydrochloride; Gefitinib; Humans; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2007 |
[Use of tyrosine kinase inhibitors in particular situations].
Topics: Bronchial Neoplasms; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2007 |
[Perspectives and future developments of epidermal growth factor receptors inhibitors].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bronchial Neoplasms; Carcinoma, Non-Small-Cell Lung; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Humans; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2007 |